RepliCel Life Sciences Inc. (REPCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 814.02 Thousand CAD | 318.78% |
| 2022 | -372.06 Thousand CAD | -99.04% |
| 2021 | -186.93 Thousand CAD | -548.68% |
| 2020 | 41.66 Thousand CAD | -90.21% |
| 2019 | 425.35 Thousand CAD | 117.59% |
| 2018 | -2.41 Million CAD | -386.53% |
| 2017 | -497.09 Thousand CAD | -718.23% |
| 2016 | -60.75 Thousand CAD | 65.44% |
| 2015 | -175.79 Thousand CAD | 67.15% |
| 2014 | -535.11 Thousand CAD | 72.67% |
| 2013 | -1.95 Million CAD | -409.52% |
| 2012 | -384.28 Thousand CAD | 21.59% |
| 2011 | -490.12 Thousand CAD | 56.87% |
| 2010 | -1.13 Million CAD | -4582.01% |
| 2009 | -24.27 Thousand CAD | -152.23% |
| 2008 | 46.47 Thousand CAD | -18.82% |
| 2007 | 57.25 Thousand CAD | 213.4% |
| 2006 | -50.48 Thousand CAD | -101.61% |
| 2005 | 3.12 Million CAD | 8.26% |
| 2004 | 2.88 Million CAD | 5917.63% |
| 2003 | 47.99 Thousand CAD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 984.77 Thousand CAD | 30.6% |
| 2024 Q2 | 1.09 Million CAD | 11.12% |
| 2023 FY | 754.02 Thousand CAD | 302.66% |
| 2023 Q4 | 754.02 Thousand CAD | 2830.76% |
| 2023 Q3 | 25.72 Thousand CAD | 114.74% |
| 2023 Q2 | -174.56 Thousand CAD | 72.68% |
| 2023 Q1 | -639.05 Thousand CAD | -71.76% |
| 2022 FY | -372.06 Thousand CAD | -99.04% |
| 2022 Q2 | -173.32 Thousand CAD | -317.98% |
| 2022 Q1 | -41.46 Thousand CAD | 77.82% |
| 2022 Q3 | -38.9 Thousand CAD | 77.55% |
| 2022 Q4 | -372.06 Thousand USD | -856.3% |
| 2021 FY | -186.93 Thousand CAD | -548.68% |
| 2021 Q4 | -186.93 Thousand CAD | 33.05% |
| 2021 Q3 | -279.22 Thousand CAD | -19.66% |
| 2021 Q1 | -405.88 Thousand CAD | -1074.21% |
| 2021 Q2 | -233.34 Thousand CAD | 42.51% |
| 2020 Q4 | 41.66 Thousand CAD | 613.03% |
| 2020 Q2 | -121.08 Thousand CAD | -699.65% |
| 2020 Q3 | -8121.00 CAD | 93.29% |
| 2020 FY | 41.66 Thousand CAD | -90.21% |
| 2020 Q1 | 20.19 Thousand CAD | -95.25% |
| 2019 Q3 | -176.66 Thousand CAD | 35.01% |
| 2019 Q4 | 425.35 Thousand CAD | 340.77% |
| 2019 FY | 425.35 Thousand CAD | 117.59% |
| 2019 Q2 | -271.83 Thousand CAD | 76.66% |
| 2019 Q1 | -1.16 Million CAD | 51.84% |
| 2018 FY | -2.41 Million CAD | -386.53% |
| 2018 Q1 | -221.36 Thousand CAD | 55.47% |
| 2018 Q2 | -48.83 Thousand CAD | 77.94% |
| 2018 Q3 | -24.46 Thousand CAD | 49.9% |
| 2018 Q4 | -2.41 Million CAD | -9785.64% |
| 2017 Q3 | -30.83 Thousand CAD | -34.57% |
| 2017 Q1 | -1.92 Million CAD | -3067.71% |
| 2017 FY | -497.09 Thousand CAD | -718.23% |
| 2017 Q4 | -497.09 Thousand CAD | -1512.16% |
| 2017 Q2 | -22.91 Thousand CAD | 98.81% |
| 2016 Q2 | -29.13 Thousand CAD | 83.39% |
| 2016 Q4 | -60.75 Thousand CAD | -202.5% |
| 2016 Q3 | -20.08 Thousand CAD | 31.06% |
| 2016 FY | -60.75 Thousand CAD | 65.44% |
| 2016 Q1 | -175.33 Thousand CAD | 0.26% |
| 2015 Q2 | -1.59 Million CAD | -55.18% |
| 2015 FY | -175.79 Thousand CAD | 67.15% |
| 2015 Q3 | -457.44 Thousand CAD | 71.36% |
| 2015 Q4 | -175.79 Thousand CAD | 61.57% |
| 2015 Q1 | -1.02 Million CAD | -92.35% |
| 2014 Q2 | -4.32 Million CAD | -218.46% |
| 2014 Q4 | -535.11 Thousand CAD | 83.81% |
| 2014 Q1 | -1.35 Million CAD | 30.67% |
| 2014 FY | -535.11 Thousand CAD | 72.67% |
| 2014 Q3 | -3.3 Million CAD | 23.56% |
| 2013 Q2 | -74.74 Thousand CAD | 85.08% |
| 2013 FY | -1.95 Million CAD | -409.52% |
| 2013 Q4 | -1.95 Million CAD | 38.08% |
| 2013 Q3 | -3.16 Million CAD | -4130.78% |
| 2013 Q1 | -500.85 Thousand CAD | -30.33% |
| 2012 Q2 | -1.5 Million CAD | 5.87% |
| 2012 FY | -384.28 Thousand CAD | 21.59% |
| 2012 Q3 | -959.17 Thousand CAD | 36.22% |
| 2012 Q4 | -384.28 Thousand CAD | 59.94% |
| 2012 Q1 | -1.59 Million CAD | -225.99% |
| 2011 Q3 | -1.13 Million CAD | 38.34% |
| 2011 Q4 | -490.12 Thousand CAD | 56.72% |
| 2011 Q2 | -1.83 Million CAD | 30.79% |
| 2011 FY | -490.12 Thousand CAD | 56.87% |
| 2011 Q1 | -2.65 Million CAD | -133.52% |
| 2010 Q2 | -31.09 Thousand CAD | 52.54% |
| 2010 Q3 | -428.13 Thousand CAD | -1276.95% |
| 2010 Q4 | -1.13 Million CAD | -165.46% |
| 2010 FY | -1.13 Million CAD | -4582.01% |
| 2010 Q1 | -65.51 Thousand CAD | -169.91% |
| 2009 Q1 | -12.57 Thousand CAD | -127.06% |
| 2009 Q4 | -24.27 Thousand CAD | 78.13% |
| 2009 Q3 | -110.98 Thousand CAD | -296.01% |
| 2009 Q2 | -28.02 Thousand CAD | -122.82% |
| 2009 FY | -24.27 Thousand CAD | -152.23% |
| 2008 Q2 | 58.74 Thousand CAD | 52.25% |
| 2008 Q4 | 46.47 Thousand CAD | -20.3% |
| 2008 Q3 | 58.31 Thousand CAD | -0.73% |
| 2008 Q1 | 38.58 Thousand CAD | -32.6% |
| 2008 FY | 46.47 Thousand CAD | -18.82% |
| 2007 Q3 | 58.82 Thousand CAD | -21.61% |
| 2007 FY | 57.25 Thousand CAD | 213.4% |
| 2007 Q1 | 8734.00 CAD | 117.3% |
| 2007 Q2 | 75.03 Thousand CAD | 759.1% |
| 2007 Q4 | 57.25 Thousand CAD | -2.67% |
| 2006 Q4 | -50.48 Thousand CAD | 81.4% |
| 2006 Q1 | 2.7 Million CAD | -13.45% |
| 2006 FY | -50.48 Thousand CAD | -101.61% |
| 2006 Q2 | -400.9 Thousand CAD | -114.81% |
| 2006 Q3 | -271.39 Thousand CAD | 32.31% |
| 2005 Q4 | 3.12 Million CAD | 1.21% |
| 2005 FY | 3.12 Million CAD | 8.26% |
| 2005 Q1 | 2.97 Million CAD | 2.89% |
| 2005 Q2 | 3 Million CAD | 1.29% |
| 2005 Q3 | 3.08 Million CAD | 2.64% |
| 2004 Q3 | 3.55 Million CAD | 28.89% |
| 2004 Q1 | 54.27 Thousand CAD | 0.0% |
| 2004 Q2 | 2.76 Million CAD | 4986.95% |
| 2004 Q4 | 2.88 Million CAD | -18.84% |
| 2004 FY | 2.88 Million CAD | 5917.63% |
| 2003 FY | 47.99 Thousand CAD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 94.836% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 80.233% |
| SQZ Biotechnologies Company | -36.23 Million USD | 102.246% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 98.098% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 112.912% |
| Mesoblast Limited | 55.85 Million USD | 98.543% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 12.205% |
| Genus plc | 190.6 Million USD | 99.573% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 63.592% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 32.941% |
| Marizyme, Inc. | 18.56 Million USD | 95.616% |
| ContraFect Corporation | -6.02 Million USD | 113.509% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -19.71% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -504.599% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 29.548% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 63.696% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 85.205% |
| MultiCell Technologies, Inc. | 90.04 USD | -903971.524% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 210.906% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 93.712% |
| EV Biologics, Inc. | 1.36 Million USD | 40.494% |
| Q BioMed Inc. | 4.06 Million USD | 79.95% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 97.336% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -30.796% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 19.221% |
| Biomind Labs Inc. | 711.4 Thousand USD | -14.426% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 99.259% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 93.644% |
| Skye Bioscience, Inc. | -5.72 Million USD | 114.228% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 5.372% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -482.262% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 85.588% |
| IMV Inc. | 7.67 Million USD | 89.388% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -3997.378% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 63.032% |
| GB Sciences, Inc. | 1.74 Million USD | 53.413% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 542.916% |
| HST Global, Inc. | 96.79 Thousand USD | -740.997% |
| CSL Limited | 10.52 Billion USD | 99.992% |
| Halberd Corporation | 144.72 Thousand USD | -462.48% |
| Enzolytics Inc. | 981.65 Thousand USD | 17.076% |
| Resverlogix Corp. | 6.45 Million USD | 87.381% |
| Affymax, Inc. | -5.59 Million USD | 114.544% |
| SYBLEU INC | 473.71 Thousand USD | -71.839% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 220.939% |
| argenx SE | -2.02 Billion USD | 100.04% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 98.126% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 101.732% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 69.947% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 109.209% |
| AVAX Technologies, Inc. | -5.9 Million USD | 113.79% |
| Zenith Capital Corp. | 10.06 Thousand USD | -7988.494% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.077% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -306.136% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 65.884% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -394.822% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.656% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 59.286% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 131.674% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -126.301% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 95.985% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 4543.858% |
| BioStem Technologies, Inc. | 4.47 Million USD | 81.797% |
| ONE Bio Corp. | 9.04 Million USD | 90.995% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -304.477% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 62239.389% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -294.742% |
| Agentix Corp. | 37.63 Thousand USD | -2063.179% |
| LadRx Corporation | -2.03 Million USD | 139.972% |
| Cell Source, Inc. | 9.23 Million USD | 91.183% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 4088.759% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -28.159% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -28.159% |
| NovAccess Global Inc. | 2.17 Million USD | 62.633% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 88.488% |
| Itoco Inc. | 228.3 Thousand USD | -256.552% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -498.597% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 83.578% |
| Kadimastem Ltd | -253.1 Thousand USD | 421.62% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -102.57% |
| CytoDyn Inc. | 20.26 Million USD | 95.982% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 125915.456% |
| Mobile Lads Corp. | 484.23 Thousand USD | -68.107% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 8882.867% |
| Qrons Inc. | 351.42 Thousand USD | -131.634% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 89.436% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 426.106% |
| Rebus Holdings, Inc. | 305 Thousand USD | -166.894% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 81.736% |
| International Stem Cell Corporation | 2.59 Million USD | 68.57% |
| Bioxytran, Inc. | 1.89 Million USD | 57.132% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1204.257% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 62.675% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 76.295% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 90.483% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -5.361% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 165.122% |
| Neutra Corp. | 52.18 Thousand USD | -1459.825% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 132.705% |
| PureTech Health plc | -167.19 Million USD | 100.487% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 432.38% |
| IXICO plc | -4.44 Million USD | 118.315% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 93.842% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 98.516% |
| CSL Limited | 10.52 Billion USD | 99.992% |
| Cellectis S.A. | -43.81 Million USD | 101.858% |